Wuppertal, Germany

Urs Lahrmann

This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.v.. Active years: 2019.


% Patents Active = 100.0


 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2019

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Urs Lahrmann in DNA Sequencing

Introduction

Urs Lahrmann is a notable inventor based in Wuppertal, Germany. He has made significant contributions to the field of DNA sequencing, particularly through his innovative methods that enhance accuracy and reliability.

Latest Patents

Lahrmann holds 1 patent for his invention titled "Error-free sequencing of DNA." This groundbreaking method involves a novel approach to sequencing DNA without errors. The invention features a four-part oligonucleotide that includes a fixed sequence, a randomized sequence, a restriction nuclease recognition site, and a primer binding site. Additionally, the sequenced DNA fragments produced by this method can be utilized in various applications, such as DNA sequence analysis, generation of cell lineage trees, and assessment of copy numbers.

Career Highlights

Urs Lahrmann is associated with the Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., a leading research organization in Germany. His work at this institution has allowed him to focus on advancing methodologies in genetic research and sequencing technologies.

Collaborations

Lahrmann has collaborated with esteemed colleagues, including Stefan Kirsch and Zbigniew Tadeusz Czyz. These partnerships have contributed to the development and refinement of his innovative sequencing techniques.

Conclusion

Urs Lahrmann's contributions to DNA sequencing represent a significant advancement in the field. His innovative methods promise to enhance the accuracy of genetic analysis and have far-reaching implications for research and medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…